Navigation Links
Renal artery stenting falls short in large randomized trial
Date:4/1/2008

CHICAGO, Ill. (April 1, 2008) The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy. Among patients who completed one year of follow-up, there were no differences in the change in kidney function, blood pressure control or the rates of major cardiovascular illness, according to the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial.

The ASTRAL trial is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

The study also found that 3 percent of patients who underwent renal artery intervention experienced a serious procedural complication, including poorly positioned stents and perforation and dissection of the renal artery.

For 15 years weve had the wherewithal to fix renal artery stenosis and restore patency of the renal artery, said Philip A. Kalra, MD, a consultant nephrologist at Hope Hospital, Salford, and lecturer at the University of Manchester, both in the United Kingdom. Thousands of patients have had this procedure, but no one has ever demonstrated any benefit in randomized control trial testing.

About 7 percent of people over age 65and about 10 percent of people with chronic kidney disease who eventually need dialysishave narrowing, or stenosis, of the renal artery. There are several links between renal artery stenosis and cardiovascular disease. For example, in nine out of 10 cases renal artery stenosis is caused by the build-up of atherosclerotic plaque. Many patients with renal artery stenosis also have coronary and peripheral arterial disease; indeed, these conditions share common risk factors. At least 30 percent of older patients with chronic congestive heart failure have renal artery stenosis. Perhaps most important, uncontrolled high blood pressure often prompts physicians to suspect renal artery stenosisand to treat it with angioplasty and stenting.

To evaluate the clinical effectiveness of renal artery stenting, Dr. Kalra and his colleagues recruited 806 patients with atherosclerotic renal vascular disease (ARVD) from 54 medical centers in the United Kingdom, and four in Australia and New Zealand. Patients had renal failure, with an average serum creatinine of about 2.0 mg/dL. Baseline blood pressure averaged 151/76 mm Hg. More than half were current or ex-smokers, nearly one-third had diabetes and nearly half had coronary artery disease. The degree of renal artery stenosis at baseline was 76 percent, on average.

The researchers randomly assigned patients to catheter-based intervention plus medical therapy or medical therapy alone. Renal artery stenting was successful in widening the renal artery, achieving a residual stenosis of less than 50 percent in 88 percent of patients.

After one year of follow-up, however, there were no differences in the change in serum creatinineit rose by 0.2 mg/dL in both groupsor in rates of renal events, including acute renal failure. Even in the highest-risk patientsthose with a baseline creatinine in the highest third, or who had experienced a rapid deterioration in kidney function in the preceding yearrenal artery angioplasty and stenting offered no significant renal functional benefit at one year, but patient numbers in these sub-groups were fairly small.

Blood pressure fell slowly over time, and by four years, averaged 146/74 mm Hg in both groups. At one year, there was no significant difference in the rates of heart attack, stroke, hospitalization for chest pain or heart failure or the need for coronary intervention or bypass surgery. Risk-adjusted mortality was the same in the two groups.

In this study we were looking at the majority of patients with renal artery stenosisthose in whom there is substantial uncertainty about whether to revascularize, Dr. Kalra said. The message is, you dont put a stent in these patients without more careful evaluation. More often than not, it will make no difference whatsoever in clinical outcomes. However, some patients with renal artery stenosis have more definite indications for revascularization, such as acute renal failure or severe acute heart failure, and they should continue to receive this therapy.

Dr. Kalra will present the results of the "Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) study on Tuesday, April 1 at 10:45 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Renal Assist Device reduces risk of death from acute kidney failure
2. Statement by Robert D. Foreman, President of The Kidney Care Council, Regarding the HHS Report to Congress A Design for a Bundled End Stage Renal Disease Prospective Payment System
3. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
4. PLC Systems Receives CE Mark Approval for RenalGuard(TM)
5. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
6. Follow-up imaging of benign-appearing incidental adrenal masses is unnecessary
7. Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care
8. Serum carcinoembryonic antigen level can reflect adrenal adenoma
9. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
10. PLC Medical Systems to Display RenalGuard(TM) During Renal Week 2007
11. Nephrologists summarize new renal research during public policy news briefing at Renal Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... VA (PRWEB) , ... May 26, 2017 , ... ... pleased to announce a new educational seminar to focus on current legislative activity ... News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will continue ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... 26, 2017 , ... Rob Lowe acts as host and helps educate and ... on hiking in American. Viewers can reconnect with America as it explores some of ... Many consumers have looked for an inventive new place for a family vacation, and ...
(Date:5/26/2017)... ... ... What Happened in the Garden of Eden”: retells the stories of three Bible figures in ... published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology: